Javascript must be enabled to continue!
Kinetic Spectrophotometric Method for the Determination of Ranitidine and Nizatidine in Pharmaceuticals
View through CrossRef
Abstract
An accurate and simple kinetic method is described for the determination of ranitidine and nizatidine in pure form and in pharmaceuticals. The method is based on the reaction of the compounds with 7-chloro-4-nitrobenz-2-oxa-1,3-diazole in pH 7.4 borate buffer at 60°C for a fixed time of 25 min for both compounds. The absorbance of the reaction product is measured at 495 nm for ranitidine and nizatidine. Calibration graphs were linear over the concentration range of 2–20 μg/mL, with limits of detection of 0.13 (3.7 × 10−7M) and 0.25 μg/mL (7.5 × 10−7M) for ranitidine and nizatidine, respectively. The proposed method was applied successfully to the determination of ranitidine in tablets and ampoules with average recoveries of 100.26 ± 0.69 and 100.29 ± 0.59%, respectively, and to the determination of nizatidine in capsules with an average recovery of 104.26 ± 0.44%. The results obtained are in good agreement with those obtained by the other methods used for comparison. A proposal of the reaction pathway is also presented.
Oxford University Press (OUP)
Title: Kinetic Spectrophotometric Method for the Determination of Ranitidine and Nizatidine in Pharmaceuticals
Description:
Abstract
An accurate and simple kinetic method is described for the determination of ranitidine and nizatidine in pure form and in pharmaceuticals.
The method is based on the reaction of the compounds with 7-chloro-4-nitrobenz-2-oxa-1,3-diazole in pH 7.
4 borate buffer at 60°C for a fixed time of 25 min for both compounds.
The absorbance of the reaction product is measured at 495 nm for ranitidine and nizatidine.
Calibration graphs were linear over the concentration range of 2–20 μg/mL, with limits of detection of 0.
13 (3.
7 × 10−7M) and 0.
25 μg/mL (7.
5 × 10−7M) for ranitidine and nizatidine, respectively.
The proposed method was applied successfully to the determination of ranitidine in tablets and ampoules with average recoveries of 100.
26 ± 0.
69 and 100.
29 ± 0.
59%, respectively, and to the determination of nizatidine in capsules with an average recovery of 104.
26 ± 0.
44%.
The results obtained are in good agreement with those obtained by the other methods used for comparison.
A proposal of the reaction pathway is also presented.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Comprehensive analysis of nizatidine: Pharmacodynamics and pharmacokinetics in anti-ulcer treatment
Comprehensive analysis of nizatidine: Pharmacodynamics and pharmacokinetics in anti-ulcer treatment
Ulcers are characterized histologically as lesions that penetrate through the muscularis mucosae into the submucosal layer, affecting any segment of the gastrointestinal (GI) tract...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Development and validation of high‐performance liquid chromatography‐Orbitrap mass spectrometric method for quantification of NDMA in ranitidine drug products and evaluation of antioxidants as inhibitors of classical nitrosation reaction
Development and validation of high‐performance liquid chromatography‐Orbitrap mass spectrometric method for quantification of NDMA in ranitidine drug products and evaluation of antioxidants as inhibitors of classical nitrosation reaction
Rationale
N
‐Nitroso dimethylamine (NDMA) is a mutagenic impurity detected in several ranitidine products. The amin...
Effectiveness Of Ranitidine Providing Compared With Omeprazol In Children With Gastroesofageal Reflux Disease
Effectiveness Of Ranitidine Providing Compared With Omeprazol In Children With Gastroesofageal Reflux Disease
Background. The drugs that are often given to children with GERD are stomach acidsuppressants, namely the H2 receptor antagonist and proton pump inhibitor (PPI) classof drugs, but ...
Evaluation of pharmacokinetic interactions of amoxicillin with ranitidine in healthy human volunteers of Karachi, Pakistan
Evaluation of pharmacokinetic interactions of amoxicillin with ranitidine in healthy human volunteers of Karachi, Pakistan
Polypharmacy may be considered as the customary practice to provide optimum care services to patients but inter resulted in augmented probability of multiple drug interaction. Keep...

